It depends. If the vaccine is producing complete regression of the in situ disease in a significant percentage of patients, it's likely not overhyped. We just don't know until we see a presentation of the data. Believe me, I want to see this work, but vaccines have a very long history of failure in I-O with the exception of those directed against tumor associated viruses. That may be about to change with checkpoint blockade combinations with vaccines. We need to keep expectations in check here until we see some real data.
News 
Market Data 
Discover 
